Related by context. All words. (Click for frequent words.) 86 Phase Ib clinical 82 phase IIa clinical 81 Phase Ib 80 phase IIb clinical 79 Phase 2a clinical 79 Phase IIb clinical 79 phase IIa 78 Phase IIa clinical 77 Phase 1a clinical 77 phase IIb 77 Phase III clinical 76 Phase 2b study 76 Phase 2a trial 76 Phase 2b clinical 76 Phase Ia 76 Phase 1b 76 Phase 1b trial 75 dose escalation Phase 75 dose escalation trial 75 Phase IIIb clinical 75 multicenter Phase II 75 Phase Ib II 74 placebo controlled Phase 74 phase Ib clinical 74 phase 2a 74 Phase IIb 74 Phase 1a 74 Phase IIa 74 phase Ib 74 Phase 2a 74 Phase 2b trial 74 Phase IIa trial 74 pivotal Phase III 74 Phase #b/#a 73 confirmatory Phase III 73 APEX PD 73 dose escalation clinical 73 Phase Ib study 73 Phase 2b clinical trials 73 Phase IIIb 72 ongoing Phase 1b 72 Phase IIb trial 72 placebo controlled clinical 72 Phase 2b 72 Phase Ib IIa 72 Phase #b/#a clinical 71 Phase III pivotal 71 randomized Phase IIb 71 Phase Ib clinical trials 71 TMC# C# 71 dose escalation study 71 placebo controlled Phase III 71 Phase #/#a 71 Phase III 71 multicenter randomized placebo controlled 70 Phase IIb trials 70 multicenter clinical 70 multicentre randomized 70 multicenter Phase 70 randomized Phase III 70 MEND CABG 70 single ascending dose 70 ADVANCE PD 70 Phase IIa trials 70 phase IIb study 70 phase IIb trial 69 BRIM2 69 Phase IIb III 69 IIa trial 69 pivotal Phase 69 JAK inhibitor 69 multiple ascending dose 69 phase IIb III 69 pharmacokinetic PK study 69 BRIM3 69 Phase III randomized controlled 69 Phase II 69 Phase III confirmatory 69 Phase #b/#a trial 69 masked placebo controlled 68 blinded randomized placebo controlled 68 oral ridaforolimus 68 Phase III clinical trials 68 FOLOTYN ® 68 randomized placebo controlled 68 Phase IIB 68 randomized multicenter 68 clinical trial 68 Phase III placebo controlled 68 double blinded randomized 68 randomized Phase 68 pharmacokinetics PK 68 randomized controlled Phase 68 elotuzumab 68 treatment naive genotype 68 rALLy clinical trial 68 Phase 2b kidney transplant 68 evaluating tivozanib 68 TG MV 68 multicenter prospective 68 Dacogen injection 68 Cloretazine ® 68 NP2 Enkephalin 68 placebo controlled 67 Phase III randomized 67 registrational 67 alvespimycin 67 double blinded placebo 67 multicenter randomized controlled 67 relapsed refractory multiple myeloma 67 IMA# 67 reslizumab 67 multicenter Phase III 67 Phase IIIb study 67 Phase 1b clinical trials 67 multicenter randomized double 67 pivotal bioequivalence 67 trastuzumab emtansine T DM1 67 INCB# [001] 67 Pivotal Phase III 67 Initiate Phase 67 Initiated Phase 67 HGS# 67 phase IIIb 67 Cloretazine R VNP#M 67 prospective multicenter 66 KRN# 66 GLP toxicology studies 66 OvaRex ® MAb 66 virus HCV protease inhibitor 66 DermaVir Patch 66 Cloretazine 66 blinded placebo controlled 66 Phase III psoriasis 66 celgosivir 66 huC# DM4 66 initiated Phase Ib 66 Archexin 66 AEGR 66 Amrubicin 66 ABSORB clinical 66 neratinib 66 confirmatory Phase 3 66 Phase IIb clinical trials 66 investigational pan BCR 66 Tarceva TM 66 preclinical efficacy 66 omacetaxine mepesuccinate 66 OncoVEX GM CSF 66 mertansine 66 ANCHOR trial 66 double blind placebo 66 TASKi2 66 randomized controlled multicenter 66 multicenter phase 66 blind randomized placebo 66 fostamatinib 66 histone deacetylase HDAC inhibitor 66 Phase 2a clinical trials 66 SCH # 66 Alzhemed TM 66 fosbretabulin 66 LUX Lung 66 multicenter randomized 66 NO# [002] 66 lomitapide 66 AQ4N 65 pertuzumab 65 trodusquemine 65 confirmatory clinical 65 ToGA 65 fidaxomicin Phase 3 65 forodesine 65 phase III ACCLAIM 65 axitinib 65 CCR5 antagonist 65 UPLYSO 65 Zenvia ™ 65 multicenter 65 lintuzumab SGN 65 pharmacokinetic PK 65 TBC# 65 randomized multicentre 65 tanespimycin 65 EDEMA3 65 SUCCEED trial 65 placebo controlled randomized 65 lorvotuzumab mertansine 65 PDE4 inhibitor 65 ZYBRESTAT fosbretabulin 65 trastuzumab DM1 T DM1 65 LCP AtorFen 65 IIa clinical trial 65 investigational compound 65 initiate Phase IIb 65 VNP#M 65 CHAMPION PCI 65 initiate Phase 1b 65 R#/MEM # 65 treatment naïve genotype 65 tolerability 65 ZACTIMA 65 CRLX# 65 PDX pralatrexate 65 Phase IIa clinical trials 65 Bicifadine 65 oral prodrug 65 FOLFOX6 chemotherapy regimen 65 AIR CF1 65 randomized blinded 65 sunitinib malate 65 PFO migraine 65 dose dose escalation 65 Mipomersen 65 Hsp# Inhibitor 65 miconazole Lauriad ® 65 Spiegelmer ® 65 randomized Phase 2b 65 CEQ# 65 tramiprosate Alzhemed TM 65 registrational trial 65 initiate Phase IIa 65 controlled multicenter 64 IIa clinical 64 teriflunomide 64 viral kinetic 64 liposomal formulation 64 multicentre 64 RSD# oral 64 randomized controlled 64 assessing T DM1 64 GetGoal Phase III 64 label multicenter 64 DASISION 64 BR.# 64 TELINTRA 64 receptor tyrosine kinase inhibitor 64 multicenter randomized Phase 64 ganetespib 64 acyclovir Lauriad R 64 Multiple Ascending Dose 64 PRTX 64 Fx #A 64 Phase 2b randomized 64 midstage trials 64 Traficet EN 64 GALNS 64 obatoclax 64 active comparator 64 relapsing multiple sclerosis 64 Omacetaxine 64 budesonide foam 64 Phase III Clinical Trial 64 Alocrest 64 Phase III trials 64 dirucotide 64 Initiates Phase II 64 bicifadine 64 dose cohort 64 ILLUMINATE 64 CCX# B 64 randomized double 64 dose cohorts 64 Randomized Phase 64 glufosfamide 64 hypoxia activated prodrug 64 volociximab 64 safety tolerability pharmacokinetics 64 LymphoStat B TM 64 thorough QT 64 Phase IIb kidney transplant 64 metaglidasen 64 Quinamed 64 Phase III multicenter 64 diabetic neuropathic pain 64 randomized clinical 64 deforolimus 64 vosaroxin 64 novel histone deacetylase 64 Androxal TM 64 EchoCRT 64 dextromethorphan quinidine 64 Zenvia Phase III 64 Vicriviroc 64 Ozarelix 64 XIENCE V Stent System 64 ENDEAVOR IV 64 non nucleoside inhibitor 64 PSMA ADC 64 QLT# 64 docetaxel Taxotere R 64 prospective randomized controlled 64 pomalidomide 64 multicenter multinational 64 blind multicenter 64 Aplidin 64 CIMZIA TM certolizumab pegol 64 TAXUS ATLAS 64 relapsed multiple myeloma 64 PS# [001] 63 Dyloject TM 63 TELCYTA 63 Aeroquin 63 HCV NS5B polymerase 63 Aflibercept 63 controlled multicenter Phase 63 multicentre randomized double 63 Allovectin 7 63 selective androgen receptor modulator 63 evaluating carfilzomib 63 PS# DARA 63 dacetuzumab 63 satraplatin Phase 63 CALGB # [002] 63 lumiliximab 63 safety tolerability 63 huN# DM1 63 lintuzumab 63 II Clinical Trial 63 Xanafide 63 davunetide intranasal AL 63 ATL# [001] 63 Urocidin 63 Combination REOLYSIN R 63 histamine dihydrochloride 63 TRANSFORMS 63 subcutaneous formulation 63 velafermin 63 melphalan prednisone 63 multicenter placebo controlled 63 romidepsin 63 riociguat 63 NVA# 63 subcutaneously administered 63 blind placebo controlled 63 dose escalation 63 elacytarabine 63 AEZS 63 ELACYT 63 MEND CABG II 63 SPIRIT FIRST 63 HCV SPRINT 63 oral rivaroxaban 63 ofatumumab HuMax CD# 63 Vascular Wrap TM 63 PEG PAL 63 COMFORT II 63 Daclizumab 63 cannabinor 63 tesmilifene 63 solithromycin 63 ABSORB trial 63 RE SURGE 63 Phenoptin 63 torezolid phosphate 63 NXL# 63 ZYBRESTAT 63 HGS ETR1 63 CA9 SCAN 63 AIR CF2 63 registrational Phase 63 entinostat 63 Phase IIb Trial 63 AVADO 63 CLARITY study 63 PRECiSE 63 Azedra 63 PEG SN# 63 rNAPc2 63 Sorafenib HCC Assessment 63 PSN# [002] 63 MAGE A3 ASCI 63 teduglutide 63 PF # [002] 63 PRX # 63 vidofludimus 63 Factor VIIa 63 Phase 2b monotherapy 63 IMGN# 63 initiate Phase 63 dirucotide MBP# 63 polymerase inhibitor 63 Valtropin 63 Pharmacokinetics PK 63 sorafenib Nexavar 63 HuMax CD4 63 CR# vcMMAE 63 VELCADE melphalan 63 VITAL Trial 63 pharmacodynamics 63 pharmacokinetic studies 63 Annamycin 63 HCV RESPOND 2 63 GLPG# 63 EmbraceAC 63 Bezielle 63 Plicera 63 ThermoDox R 63 ocular formulation 63 Tyrima 63 adecatumumab 63 prospective multicenter randomized 63 ascending dose 63 refractory CLL 63 nab paclitaxel 63 OncoGel 63 transcriptase inhibitor NNRTI 63 SNT MC# 63 YONDELIS 63 HuMax EGFr 63 multicenter randomized clinical 63 SAR# [004] 63 oral deforolimus 63 cathepsin K inhibitor 63 TMC# [002] 63 blind randomized 63 randomized discontinuation trial 63 IL# PE#QQR 63 vascular disrupting agent 63 pharmacodynamic PD 63 amrubicin 63 PEP# [003] 63 EXPLORE Xa 63 ONTARGET 63 Reolysin 63 Phase #/#a clinical 63 blinded randomized 63 randomized multicenter Phase III 63 Aurexis 63 Dalbavancin 63 Pivotal Phase 62 PD LID 62 TLK# 62 CLIRS trial 62 brivaracetam 62 OncoVEX 62 BCIRG 62 EVEREST II 62 PHX# 62 relapsed MM 62 MIST II 62 PEG IFN 62 Aryplase 62 prospective randomized 62 Phase lll 62 investigational protease inhibitor 62 bendamustine 62 investigational humanized monoclonal antibody 62 Phase IIA 62 ENDEAVOR III 62 REMUNE R 62 aflibercept 62 metastatic hormone refractory 62 RE LY 62 cell lymphoma CTCL 62 rilonacept 62 Safinamide 62 Glufosfamide 62 telaprevir VX 62 alemtuzumab Campath 62 designated HVTN 62 label dose escalation 62 AZILECT R 62 Phase IIB clinical 62 Darusentan 62 CB2 selective receptor agonist 62 PRT# 62 vicriviroc 62 OHR/AVR# 62 RH1 62 AKT inhibitor 62 Aurora kinase inhibitor 62 nitazoxanide 62 pradefovir 62 afatinib 62 tolevamer 62 Ophena TM 62 #th Annual Interscience 62 TASKi3 62 AEG# 62 dosing cohorts 62 unblinding 62 Phase III VISTA 62 Corlux 62 Zybrestat 62 PANVAC VF 62 evaluating REVLIMID 62 farletuzumab 62 MERLIN TIMI 62 Sym# 62 Onconase 62 AIM HIGH 62 TRX1 62 GAMMAGARD 62 RE LY ® 62 Ceflatonin R 62 Telatinib 62 investigational antiplatelet agent 62 oral methylnaltrexone 62 Panzem R NCD 62 mapatumumab 62 Prosaptide 62 Luveniq 62 APPRAISE 62 Elagolix 62 TRO# 62 nucleotide analog 62 PRIMO CABG 62 CRMD# 62 Diamyd ® 62 Proxinium TM 62 ceftazidime 62 desvenlafaxine succinate 62 Tesetaxel 62 Amoxicillin PULSYS Phase III 62 PRE SURGE 62 Troxatyl 62 Asentar 62 PREOS 62 EOquin 62 MAP# 62 STRIDE PD 62 CG# [003] 62 CRx 62 ruxolitinib 62 Intervention Effectiveness 62 refractory chronic lymphocytic 62 Pegasys plus Copegus 62 enzastaurin 62 Catena ® 62 Enzastaurin 62 Luteinizing Hormone Releasing Hormone 62 Augment Injectable 62 Firazyr 62 Denufosol 62 orally bioavailable 62 AzaSite Plus 62 bosutinib 62 recurrent malignant glioma 62 PrevOnco 62 crizotinib PF # 62 initiate Phase 2b 62 Phase III metastatic melanoma 62 DEB# 62 evaluating satraplatin 62 visilizumab 62 HCD# [002] 62 RG# [001] 62 RhuDex ® 62 CIMZIA TM 62 Pimavanserin 62 ritonavir boosted 62 ENESTnd 62 resminostat 62 VICTOR E1 62 safety tolerability pharmacokinetic 62 ADAGIO study 62 prospective randomized multicenter 62 Pivotal Trial 62 topical formulation 62 prospective randomized placebo 62 COU AA 62 ORENCIA ® 62 Maximum Tolerated Dose MTD 62 Lucanix R 62 Phase 2b Clinical Trial 62 metastatic renal cell carcinoma 62 BOLDER II 62 Omigard 62 Lu AA# 62 GRNVAC1 62 null responder HCV 62 AeroLEF TM 62 inhibitor RG# 62 EOquin TM 62 PEG Interferon lambda 62 AVONEX ® 62 cilengitide 62 Fodosine 62 Laquinimod 62 perifosine 62 Marqibo 62 Phase III Psoriasis 61 ocrelizumab 61 REVIVE Diabetes 61 Amplimexon 61 Shigamabs ® 61 APEX AMI trial 61 Silodosin 61 Plecanatide 61 GW# [003] 61 interferon gamma 1b 61 Carfilzomib 61 BNC# 61 Oral NKTR 61 investigational drug 61 CoFactor 61 initiate Phase Ib 61 TG# [001] 61 BRAF inhibitor 61 CBLC# 61 Prodarsan 61 LEP ETU 61 gemcitabine Gemzar ® 61 ACTEMRA TM 61 incyclinide 61 DB# [003] 61 NASDAQ CXSP announced 61 PI3K/Akt pathway inhibitor 61 IDX# 61 LUMINATE 61 MGd 61 Dapagliflozin 61 European Sepsis Trial 61 Ixempra 61 Onalta ™ 61 REOLYSIN ® 61 PXD# 61 Raptiva ® 61 generation PNP inhibitor 61 RELOVAIR ™ 61 CYT# 61 CA4P 61 Diabetic Macular Edema DME 61 preclinical studies 61 lexidronam injection 61 Myocet 61 PNP inhibitor 61 Tolvaptan 61 stated Michelle Berrey 61 Tarvacin TM 61 IIa clinical trials 61 Diabetic Macular Edema 61 RG# ITMN 61 investigational oral 61 Azixa 61 Phase 61 IMPACT IMmunotherapy 61 Hyphanox 61 NSABP B 61 BiTE R 61 APTIVUS 61 CLORETAZINE TM VNP#M 61 XL# XL# XL# 61 EGS# 61 evaluating Vectibix 61 MEK inhibitor 61 Perifosine 61 BLOOM DM 61 candidate AQ4N 61 lead Aganocide compound 61 Loramyc R 61 sNDA submission 61 Phase III Trial 61 radiation sensitizer 61 IIb clinical trial 61 TG# [003] 61 Hedgehog Pathway Inhibitor 61 evaluating Actimmune 61 balsalazide tablet 61 Imprime PGG 61 photoprotective drug 61 initiated Phase 1b 61 Fibrillex TM 61 antibody MAb 61 EndoTAG TM -1 61 GOUT 61 vemurafenib 61 Meets Primary Endpoint 61 metastatic HRPC 61 Diamyd R 61 Veronate 61 ofatumumab 61 ancrod 61 Phase 1b dose escalation 61 Phase #/#a trial 61 zanolimumab 61 Pivotal Study 61 LCP Tacro 61 custirsen 61 seliciclib CYC# 61 WX UK1 61 ProSavin 61 randomized controlled clinical 61 XL# SAR# 61 SinuNase TM 61 Phase III Pivotal 61 ThermoDox ® clinical 61 midstage clinical 61 Betaferon ® 61 Triapine 61 prospective observational 61 telomerase inhibitor drug 61 Randomised 61 generation purine nucleoside 61 torezolid 61 clinical trials 61 refractory gout 61 HPTN 61 immunotherapeutic agent 61 IIa trials 61 CUSTOM III 61 trial evaluating PRX# 61 Sapacitabine 61 LE SN# 61 Multicenter 61 Pralatrexate 61 Blinatumomab 61 Nuvion 61 tolerated dose MTD 61 Cimzia ® certolizumab pegol 61 aclidinium bromide 61 Phase III HEAT 61 FTY# fingolimod 61 Completes Patient Enrollment 61 isavuconazole 61 REG2 61 anticancer compound 61 NGX# 61 Personalized Immunotherapy 61 CLL8 61 Iluvien ® 61 mTOR inhibitor 61 Microplasmin 61 Revlimid lenalidomide 61 cangrelor 61 Proellex TM 61 temsirolimus 61 Phase 2a proof 61 dose escalation phase 61 sulodexide 61 Prostate AdenoCarcinoma Treatment 61 HCV protease inhibitor 61 ONCONASE R 61 orally inhaled migraine 61 RDEA# 61 palifosfamide 61 IND enabling 61 ALN TTR# 61 Aptivus ® 61 opioid induced bowel dysfunction 61 Cimzia TM 61 Clinical Antipsychotic Trials 61 tremelimumab 61 MIRCERA 61 Romidepsin 61 valopicitabine 61 Serdaxin ® 61 IMC A# 61 galiximab 60 Viramidine 60 Achieves Primary Endpoint 60 compound INCB# 60 RGB # 60 refractory metastatic colorectal cancer 60 novel oral anticoagulant 60 oral antiviral 60 PREOS R 60 rALLy trial 60 afamelanotide 60 AP# [003] 60 eltrombopag 60 Cethromycin 60 BAY #-# 60 castrate resistant prostate cancer 60 Dacogen decitabine 60 Pafuramidine 60 Curaxin CBLC# 60 ascending doses 60 Omapro 60 ketolide antibiotic 60 apricitabine 60 Pivotal Phase II 60 PEGylated interferon beta 1a 60 Aplidin R 60 Ereska 60 MAA submission 60 GV# [001] 60 Medidur TM FA 60 BrachySil TM 60 TOCOSOL Paclitaxel 60 ILUVIEN ® 60 monotherapy 60 ORMD 60 Anturol TM 60 PERSEUS 60 Vicinium TM 60 proteasome inhibitor 60 CALGB 60 ponatinib 60 mRCC 60 evaluating Xcytrin 60 paclitaxel poliglumex 60 Phase III registrational 60 personalized immunotherapy 60 antiviral efficacy 60 #mg QD [002] 60 evaluating mipomersen 60 cariprazine 60 intranasal formulation 60 Cloretazine R 60 Prodarsan ® 60 prucalopride 60 randomized multicenter trial 60 palonosetron 60 First Patient Dosed 60 orally administered inhibitor 60 MT# MEDI 60 StemEx 60 miconazole Lauriad R 60 Alpharadin 60 Degarelix 60 eosinophilic asthma 60 mitogen activated ERK kinase 60 ceftaroline 60 severe hypercholesterolemia 60 non nucleoside HCV 60 MLN# 60 HQK 60 NOX E# 60 PROVENGE ® 60 OncoVex 60 ELND# 60 JAK2 inhibitor 60 LibiGel Phase III 60 StemEx R 60 dyskinesia PD LID 60 alvimopan 60 XmAb# 60 EFAPROXYN 60 Allovectin 7 R 60 TEMSO 60 Phase III Clinical Trials 60 systemic RNAi therapeutic 60 maturation inhibitor 60 Ophena 60 Acetavance TM intravenous acetaminophen 60 ATL/TV# 60 Glybera R 60 HepeX B TM 60 RezularTM 60 unique alkylating agent 60 pharmacokinetic 60 HER2 positive metastatic breast 60 ganaxolone 60 ISTODAX ® 60 clinicaltrials 60 Telintra 60 ENDEAVOR II 60 CLARITY TIMI 60 ProLindac 60 baminercept 60 NCCTG 60 Phase Ib IIa clinical 60 MabCampath 60 HIV integrase inhibitor 60 XL# anticancer compounds 60 NS5A inhibitor 60 targeted radiotherapeutic 60 PROSTVAC TM 60 RE COVER 60 Altastaph 60 doxorubicin docetaxel 60 TASQ 60 unblinded 60 3 registrational trial 60 CIMZIA ™ 60 ICA # 60 Anturol 60 bevirimat Study 60 Zoraxel 60 fidaxomicin Phase 60 elagolix 60 pralatrexate injection 60 Phase 2a preventative 60 BCX# 60 Dextofisopam 60 evaluable patients 60 IMPACT DCM clinical 60 Zerenex ™ 60 HDAC Inhibitor 60 ACOMPLIA R 60 Pirfenidone 60 L Annamycin 60 ixabepilone 60 Initiate Phase II 60 BioNumerik 60 palifosfamide Zymafos TM 60 carboplatin paclitaxel 60 BEMA TM Fentanyl 60 Vectibix panitumumab 60 pharmacodynamic properties 60 ZD# [001] 60 acyclovir Lauriad ® 60 novel nucleoside analog 60 PLK1 SNALP 60 IPL# 60 CLIRS 60 Nexavar ® 60 bevacizumab Avastin 60 Genasense ® 60 Apoptone 60 trabedersen 60 CDP# 60 MEK inhibitor RDEA# 60 KB# [002] 60 Allovectin 7 ® 60 Locteron ® 60 #I TM# 60 ROCKET AF 60 Ceflatonin 60 BrachySil ™ 60 Omnitarg 60 MIVI III 60 painful diabetic neuropathy 60 Besivance 60 ongoing Phase IIIb 60 MORAb 60 LibiGel ® 60 GRN#L 60 SUTENT ® 60 ataluren 60 protein kinase inhibitor 60 omega interferon 60 humanized monoclonal antibody 60 albinterferon alfa 2b 60 Elocalcitol 60 GSK# [002] 60 ORACLE MS 60 stage IIIB 60 relapsing remitting multiple sclerosis 60 label multicenter Phase 60 daclizumab 60 iniparib 60 LEUKINE 60 SPRYCEL ® 60 SinuNase 60 Guanilib 60 IMPACT DCM 60 telaprevir dosing 60 Cethrin R 60 glucokinase activator 60 TMC# [001] 60 CTAP# Capsules 60 Velcade bortezomib 60 pharmacodynamic profile 60 ritonavir boosted danoprevir 60 TOLAMBA 60 Parkinson disease levodopa induced 60 CANCIDAS 60 preclinical 60 Pegasys ® 60 OMP #M# 60 RoACTEMRA 60 investigational monoclonal antibody 59 HspE7 59 Zemplar Capsules 59 EDEMA4 59 Hsp# inhibitor 59 INSPIRE Trial Phase III 59 Nasdaq PGNX today 59 apricitabine ATC 59 Gabapentin GR 59 CAMMS# 59 HGS ETR2 59 CCX# 59 CML CP 59 safinamide 59 rasagiline tablets 59 MT#/MEDI-# 59 novel VDA molecule 59 RSD# 59 REVLIMID lenalidomide 59 Kahalalide F 59 diarrhea predominant irritable 59 Panzem R 59 Nasdaq NYMX 59 Phase IIb Clinical Trial 59 SNT-MC#/idebenone 59 EURIDIS 59 MGCD# [001] 59 Tanespimycin 59 Virulizin R 59 Akt inhibitor 59 evaluating bafetinib 59 icatibant 59 Vilazodone 59 darunavir ritonavir 59 Trofex 59 Teysuno 59 Ketotransdel 59 Successfully Completes Phase 59 MINDSET 59 GEM OS1 59 Presents Preclinical 59 KNS # 59 ulimorelin 59 Endovascular Valve Edge 59 metastatic castrate resistant